4Gambino R. C-reactive protein-undervalued, underutilized. Clin Chem, 1997,43:2017 -2018.
5Cano NJ, Pichard C, Roth H, et al C-reactive protein and body mass index p red ict outcome in end-stage respiratory failure. Chest,2004. 126(2) :540-546.
4Miyashita N, Obase Y, Ouchi K, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit[ J]. J Med Microbiol,2007,56 ( Pt 12 ) : 1625 - 1629.
5Youn YS, Lee KY, Hwang JY, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia [ J ]. BMC Pediatr, 2010,10:48.
6Vervloet LA, Marguet C, Camargos PA. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias [ J ]. Braz J Infet Dis, 2007, 11 (5) :507 -514.
7Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children [ J ]. Pediatr Pulmonol,2006,41 ( 3 ) :263 - 268.
8Tamura A, Matsubara K ,Tanaka T, et al. Methylprednisolone pulse ther- apy for refractory Mycoplasma pneumoniae pneumonia in children[J]. J Infect, 2008,57 (3) : 223-228.
9Ferwerda A, Moll HA, de Groot R. Respiratory tract infections by My- coplasma pneumoniae in children: a review of diagnostic and therapeutic measures[J]. Eur J Pediatr, 2001,160 ( 8 ) : 483-491.
10Youn YS,Lee KY,Hwang JY,et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia[J]. BMC Pediatr,2010,10 : 48.
